Please login to the form below

Not currently logged in
Email:
Password:

Opdivo

This page shows the latest Opdivo news and features for those working in and with pharma, biotech and healthcare.

AZ drug matched to cancer mutation passes phase 2 test

AZ drug matched to cancer mutation passes phase 2 test

The first approvals for type-agnostic therapies have already been granted, with Merck/MSD’s Keytruda (pembrolizumab( and Bristol-Myers Squibb’s Opdivo (nivolumab) – both PD-1 checkpoint inhibitors – greenlighted for

Latest news

More from news
Approximately 123 fully matching, plus 168 partially matching documents found.

Latest Intelligence

  • The handover: Pfizer reshapes itself for a new era The handover: Pfizer reshapes itself for a new era

    The therapy area is dominated by Merck’s Keytruda, BMS’Opdivo and Roche’s Tecentriq, but Pfizer is hoping that combinations such as its own Inlyta and Bavencio can help it

  • Chinese biotech’s global ambitions Chinese biotech’s global ambitions

    their blockbuster checkpoint inhibitors Keytruda and Opdivo. ... CDA). The company is filing first for patients with relapsed/refractory classical Hodgkin’s lymphoma (R/R cHL) – a niche indication not yet taken in China by Keytruda and Opdivo, which

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    It’s not all been plain sailing, with BMS’Opdivo (nivolumab) and Roche’s Tecentriq not doing as well as hoped in frontline NSCLC, revealing there are differences between checkpoint inhibitors – ... Opdivo after standard treatment of early-stage

  • The good, the bad and the ugly The good, the bad and the ugly

    Though its main competitor, BMS’Opdivo, was first to the NSCLC market, Merck’s frontline trial for Keytruda succeeded whereas Opdivo’s failed.

  • Accelerating innovation Accelerating innovation

    Leading this work is an agreement with Bristol-Myers Squibb to study a combination of Cabometyx and that firm’s blockbuster immuno-oncology drug Opdivo (nivolumab) and an agreement with Roche

More from intelligence
Approximately 0 fully matching, plus 10 partially matching documents found.

Latest appointments

  • BMS appoints CCO, Stephen Davies joins Eisai and more BMS appoints CCO, Stephen Davies joins Eisai and more

    The move comes at a challenging time for BMS, as its blockbuster immunotherapy Opdivo has just been overtaken in global revenues by its arch-rival, Merck &Co's Keytruda. ... BMS looks unlikely to take the lead again, but Boerner can ensure Opdivo remains

  • BMS appoints oncology development head BMS appoints oncology development head

    On moving to the US in 2006, Dr Namouni took over responsibility for metastatic colorectal cancer treatment Erbitux (cetuximab), before serving as development lead for Opdivo (nivolumab) and Yervoy (ipilimumab).

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • A stumble, but not a fall – what’s next for Opdivo?

    Bristol-Myers Squibb's (BMS, $BMY) immunotherapy wonder drug  Opdivo (nivolumab) was poised for lasting success. ... Some chinks in the Opdivo armor were evident back in June 2016, but were largely overlooked.

  • Video: Immuno-oncology therapies

    However, these therapies come with a very high price tag and currently only a few of these drugs have actually reached the market including Opdivo, Keytruda and Yervoy.

  • Video: Immuno-oncology therapies

    However, these therapies come with a very high price tag and currently only a few of these drugs have actually reached the market including Opdivo, Keytruda and Yervoy.

  • ASCO 2015: What you missed in Chicago

    Bristol-Myers-Squibb redefines Melanoma treatment standards. In terms of winners here, BMS is likely to redefine the standard of care in Melanoma with the Opdivo/Yervoy (ipilimumab) combination. ... challenge Opdivo will depend on how the European

  • Blue Latitude Health

    A stumble, but not a fall – what’ s next for Opdivo?. ... Blue Latitude Health's Louis Perdios talks about the daunting challenges faced by BMS after Opdivo's disappointing results.

More from PMHub
Approximately 1 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics